Celldex (CLDX)
32.45
-0.48 (1.46%)
Upcoming Events
Latest Headlines
UBS Reiterates Buy Rating on Celldex Therapeutics (CLDX)
June 16, 2026 9:28 AM - StreetInsider
Celldex reports sustained angioedema improvements 7 months post-treatment
June 14, 2026 2:00 PM - StreetInsider
Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual
June 14, 2026 10:21 AM - Globe NewsWire
Celldex reports positive phase 1 results for bispecific antibody CDX-622
June 14, 2026 5:15 AM - StreetInsider
Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting
June 14, 2026 5:15 AM - Globe NewsWire
Celldex to present mast cell targeting drug data at European congress
June 10, 2026 4:01 PM - StreetInsider
Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual CongressÂ
June 10, 2026 4:01 PM - Globe NewsWire
Celldex Therapeutics (CLDX) PT Raised to $45 at UBS
June 10, 2026 8:37 AM - StreetInsider
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Kynam Capital Management, LP
May 15, 2026 4:02 PM - SEC Filing
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: Bellevue Group AG
May 15, 2026 2:37 PM - SEC Filing
Celldex Therapeutics (CLDX) PT Raised to $54 at Wells Fargo
May 13, 2026 6:04 AM - StreetInsider
Form SCHEDULE 13G Celldex Therapeutics, Filed by: STATE STREET CORP
May 12, 2026 10:19 AM - SEC Filing
Celldex Therapeutics (CLDX) PT Raised to $48 at Barclays
May 8, 2026 4:05 AM - StreetInsider
Celldex (CLDX) Tops Q1 EPS by 1c
May 7, 2026 5:45 PM - StreetInsider
Form 10-Q Celldex Therapeutics, For: Mar 31
May 7, 2026 4:09 PM - SEC Filing
Form 8-K Celldex Therapeutics, For: May 07
May 7, 2026 4:02 PM - SEC Filing
Celldex Reports First Quarter Financial Results and Provides Corporate Update
May 7, 2026 4:01 PM - Globe NewsWire
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: FMR LLC
May 6, 2026 11:07 AM - SEC Filing
Form SCHEDULE 13G Celldex Therapeutics, Filed by: VANGUARD CAPITAL MANAGEMENT LLC
April 29, 2026 5:36 PM - SEC Filing
Form ARS Celldex Therapeutics, For: Dec 31
April 29, 2026 8:02 AM - SEC Filing
Form DEF 14A Celldex Therapeutics, For: Jun 25
April 29, 2026 8:01 AM - SEC Filing
Barclays Double Upgrades Celldex Therapeutics (CLDX) to Overweight
April 20, 2026 3:59 AM - StreetInsider
Celldex to Present at Upcoming Investor Conference
April 13, 2026 4:01 PM - Globe NewsWire
Celldex Therapeutics closes $345 million stock offering
April 6, 2026 10:54 AM - StreetInsider
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 6, 2026 10:53 AM - Globe NewsWire
Form 424B5 Celldex Therapeutics,
April 2, 2026 5:15 PM - SEC Filing
Form 8-K Celldex Therapeutics, For: Apr 01
April 2, 2026 8:08 AM - SEC Filing
Celldex prices $300 million stock offering at $29 per share
April 1, 2026 9:48 PM - StreetInsider
Celldex Announces Pricing of $300 Million Public Offering of Common Stock
April 1, 2026 9:48 PM - Globe NewsWire
Form 424B5 Celldex Therapeutics,
April 1, 2026 4:08 PM - SEC Filing
Celldex launches public offering of common stock
April 1, 2026 4:01 PM - StreetInsider
Celldex Announces Proposed Public Offering of Common Stock
April 1, 2026 4:01 PM - Globe NewsWire
Celldex reports quality of life gains in urticaria studies
March 27, 2026 10:30 AM - StreetInsider
Celldex Presents Positive Data from Phase 2 Chronic Spontaneous Urticaria and Phase 2 Cold Urticaria and Symptomatic Dermographism Studies Demonstrating Rapid, Profound and Durable Improvements in Pat
March 27, 2026 10:30 AM - Globe NewsWire
Form SCHEDULE 13G/A Celldex Therapeutics, Filed by: VANGUARD GROUP INC
March 26, 2026 5:17 PM - SEC Filing
Wolfe Research Upgrades Celldex Therapeutics (CLDX) to Outperform
March 23, 2026 5:40 AM - StreetInsider
Full Article List
